The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000818336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/06/2026
Date registered
Help: Date registered
8/07/2026
Date last updated
Help: Date last updated
23/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
8/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The EEEP Trial: Evaluating the Effectiveness of EmoLED Photobiomodulation Therapy for venous leg ulcers
Scientific title
Evaluating the Effectiveness of EmoLED Photobiomodulation Therapy as an Adjunct to Standard of Care in the Management of Venous Leg Ulcers, The EEEP Randomised Controlled Trial
Additional trial identifiers [1] 317446 0
Nil
Universal Trial Number (UTN)
Trial acronym
EEEP Trial
Related trial records

Health condition
Health condition(s) studied:
Venous leg ulcers 342142 0
Structural or functional venous disease and ulcers. 342431 0
Condition category
Condition code
Skin 338252 338252 0 0
Other skin conditions
Physical Medicine / Rehabilitation 338253 338253 0 0
Other physical medicine / rehabilitation
Cardiovascular 338254 338254 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Arm 1 will receive standard wound care twice weekly for four weeks (weeks 1-4) and again in week 6. Standard wound care (once a week at the study site (vascular surgery or aged care facility) with a wound care nurse and once a week with community nursing) will be combined with the intervention which is weekly EmoLED therapy for the first four weeks. In weeks 5, 7, 8, 9, 10 and 11, participants will receive wound care from community nurses twice weekly. Participants in Arm 1 will also receive resources for skin care, wound care, exercise and diet at baseline as part of standard care. The skin care, wound care and exercise brochures are general guidance and standard care within the Vascular One setting. The diet resource provided will be the Australian Guide to Healthy Eating Adult Serves guide.

Standard care will take 45 minutes if wounds are on one leg or 1 hour and 15 minutes if bilateral wounds. The EmoLED treatment will take 10 minutes - this will be catered for in the standard care time to ensure there is no addition time taken for the intervention group, reinforcing blinding.

The EmoLEDâ„¢ (Florence, Italy) device delivers photobiomodulation therapy using blue light wavelengths specifically designed for wound care applications. The EmoLEDâ„¢ therapy will be provided at the study site after wound bed preparation and before wound dressings are applied. It will be conducted by a wound care nurse or a vascular surgeon who are part of the research team.
The device parameters are:
- Spectral bandwidth: 400-430nm
- Power density/irradiance: 120mW/cm2
- Irradiated area: 20cm
- Energy density/fluence: 14,4 j/cm2.
- Treatment distance: 3-5cm (distance from sensor inside)
- Power output: 2,3 W – max emission variation 1%
- Time: 120 seconds

Adherence will be captured in REDCap which includes study visits as well as community nurse standard wound care details.
Intervention code [1] 334239 0
Treatment: Devices
Description of the comparator or control
Arm 2: Standard wound care only (control)
Standard wound care involves once a week at the study site (vascular surgery or aged care facility) with a wound care nurse and once a week with community nursing for four weeks, as well as in week 6. Participants in the control group will also receive educational brochures for skin care, wound care, exercise and diet at baseline. The skin care, wound care and exercise brochures are general guidance and standard care within the Vascular One setting. The diet resource provided will be the Australian Guide to Healthy Eating Adult Serves guide. In weeks 5, 7, 8, 9, 10 and 11, participants will receive wound care from community nurses twice weekly.

Standard care will take 45 minutes if wounds are on one leg or 1 hour and 15 minutes if bilateral wounds.

Adherence will be captured in REDCap which includes study visits as well as community nurse standard wound care details.
Control group
Active

Outcomes
Primary outcome [1] 345615 0
Proportion completely healed at 12 weeks, with completely healed defined as completely epithelialized.
Timepoint [1] 345615 0
The primary outcome (proportion of wounds healed at 12 weeks) is reliant on wound measures, which are measured at all time points - Weeks 1, 2, 3, 4, 6 and 12 post-randomisation and post-treatment commencement. Week 12 is the primary timepoint.
Secondary outcome [1] 462429 0
Ulcer length (cm)
Timepoint [1] 462429 0
Weeks 1, 2, 3, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [2] 462430 0
Clinical signs and symptoms of infection
Timepoint [2] 462430 0
Weeks 1, 2, 3, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [3] 462431 0
Pain
Timepoint [3] 462431 0
Weeks 1, 2, 3, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [4] 462432 0
Quality of life
Timepoint [4] 462432 0
Weeks 1, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [5] 462433 0
Wound bed readiness for healing
Timepoint [5] 462433 0
Weeks 1, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [6] 462434 0
Pitting oedema
Timepoint [6] 462434 0
Weeks 1, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [7] 463547 0
Ulcer width (cm)
Timepoint [7] 463547 0
Weeks 1, 2, 3, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [8] 463548 0
Ulcer depth (mm)
Timepoint [8] 463548 0
Weeks 1, 2, 3, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [9] 463549 0
Wound volume (cm3)
Timepoint [9] 463549 0
Weeks 1, 2, 3, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [10] 463552 0
Ulcer perimeter (cm)
Timepoint [10] 463552 0
Weeks 1, 2, 3, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [11] 463553 0
Ulcer area (cm²)
Timepoint [11] 463553 0
Weeks 1, 2, 3, 4, 6, and 12 post-randomisation and post-treatment commencement.
Secondary outcome [12] 463554 0
The average linear healing of the wound edge.
Timepoint [12] 463554 0
Weeks 1 and 12 post-randomisation and post-treatment commencement.

Eligibility
Key inclusion criteria
Inclusion criteria for the study:
Adults
AND
Presence of chronic lower leg venous ulcer (Greater than or equal to 6 weeks duration) with a surface area of less than or equal to 80cm2
AND
Ulcer is not circumferential
AND
Able to attend the required number of clinic visits for wound dressings
AND
Can provide written informed consent and complete questionnaires or informed consent and questionnaires can be completed by the legal person responsible

As the maximum diameter of the EmoLED treatment beam is 5cm (surface area of 19.6cm2) and chronic ulcers require 120 seconds irradiation per application, the maximum ulcer surface area that can be included is 80cm2, equal to a maximum of four consecutive applications (a total of 8 minutes).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion criteria for the study:
Wound present for less than 6 weeks
OR
Wound greater than 80cm2
OR
Circumferential ulcers
OR
Malignant ulcers
OR
Arterial ulcers with Toe Brachial Index (TBI) less than 0.5 or Ankle Brachial Pressure Index (ABPI) less than 0.6
OR
Pressure ulcers

Use of other advanced therapies such as Negative Pressure Wound Therapy (NPWT), grafting, topical oxygen therapy
OR
Presence of untreated osteomyelitis, spreading or systemic infection
OR
Previous treatment with photo biomodulation therapy
OR
Pregnancy or breastfeeding
OR
Unable to provide informed consent or complete questionnaires

The ulcer cannot be circumferential as the ulcer needs to be photographed to measure the wound using the Wound Genius phone application (imito AG, Zurich Switzerland).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
One researcher will conceal sequence generation and only inform the researcher conducting the intervention assignment of the intervention once the participant has been randomised.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Group allocation will be determined by a computer-generated block randomisation method integrated into REDCap software. Participants will be randomised in fixed blocks of 6 and a 1:1 ratio. Participants are randomised at the baseline visit.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
STATA/BE 17.0 (StatCorp LLC., College Station, TX, USA) software will be utilised for data analysis. Categorical variables will be presented as counts and percentages, and continuous variables reported as mean and standard deviation (SD), unless evidence of non-normality and therefore, median and inter-quartile range (IQR) will be presented. The primary outcome, complete wound healing at 12 weeks (yes/no), will be analysed using log-binomial regression, with treatment group (EMOLED vs. standard care) as the primary predictor. If the log-binomial model fails to converge, Poisson regression with robust (sandwich) standard errors will be used as a pre-specified alternative; both approaches yield a Risk Ratio (RR) with 95% confidence interval as the effect estimate. The model will be adjusted for baseline ulcer area (log-transformed to account for skewness), and ulcer duration, pre-specified as prognostic covariates. The adjusted RR and its 95% CI will be the primary effect estimate, with a two-sided p-value threshold of 0.05. All randomised participants will be included in the primary analysis on an intention-to-treat basis. The impact of missing primary outcome data will be explored in a sensitivity analysis using multiple imputation under a missing-at-random assumption, with results compared to the complete-case analysis.

Linear mixed-models will be performed for secondary continuous outcomes, with maximum likelihood estimation and robust (sandwich) standard errors to assess the change of the intervention on efficacy outcomes, with time (weeks 1, 2, 3, 4, 6 and 12) and treatment group (control and intervention) as predictors, and group x time as an interaction term. Models will be checked for fit and whether they meet assumptions. The model will be adjusted for baseline ulcer area (log-transformed to account for skewness) and ulcer duration, pre-specified as prognostic covariates. Post-estimations will be reported as mean and 95% CI. Significance will be set at 0.05, and p-values and 95% confidence intervals (95%CI) will be utilised to determine statistical significance. The primary estimate of treatment effect will be the group × time interaction term, reflecting the differential change between groups over the follow-up period. Within-group changes will be reported descriptively but will not be used for inferential comparisons. Standardised effect sizes will be calculated by dividing the model coefficients by the baseline standard deviation and classified as small (d=0.2), medium (d=0.5) or large (d=0.8). For secondary outcomes, no correction for multiplicity will be applied and secondary outcomes should be interpreted as exploratory.

Binary outcomes (including pitting oedema, NERDS and STONES) will be analysed using a generalised linear mixed model (GLMM) with a random intercept per participant and a logit link, consistent with the missing-at-random assumption adopted throughout. Should convergence fail, generalised estimating equations with robust standard errors and an exchangeable working correlation structure will be used as a pre-specified alternative.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322020 0
Commercial sector/Industry
Name [1] 322020 0
Te Arai BioFarma.
Country [1] 322020 0
Australia
Funding source category [2] 322191 0
Commercial sector/Industry
Name [2] 322191 0
Kerr Biotech
Country [2] 322191 0
Australia
Primary sponsor type
Other
Name
Vascular One
Address
Country
Australia
Secondary sponsor category [1] 324898 0
None
Name [1] 324898 0
Address [1] 324898 0
Country [1] 324898 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320553 0
Monash University Human Research Ethics Committee
Ethics committee address [1] 320553 0
Ethics committee country [1] 320553 0
Australia
Date submitted for ethics approval [1] 320553 0
23/03/2026
Approval date [1] 320553 0
01/06/2026
Ethics approval number [1] 320553 0
50324

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150850 0
Dr Peta Tehan
Address 150850 0
246 Clayton Road, Department of Surgery, School of Clinical Sciences, Monash University, Clayton, Victoria, 3168
Country 150850 0
Australia
Phone 150850 0
+61 403 704 912
Fax 150850 0
Email 150850 0
Contact person for public queries
Name 150851 0
Peta Tehan
Address 150851 0
246 Clayton Road, Department of Surgery, School of Clinical Sciences, Monash University, Clayton, Victoria, 3168
Country 150851 0
Australia
Phone 150851 0
+61 403 704 912
Fax 150851 0
Email 150851 0
Contact person for scientific queries
Name 150852 0
Peta Tehan
Address 150852 0
246 Clayton Road, Department of Surgery, School of Clinical Sciences, Monash University, Clayton, Victoria, 3168
Country 150852 0
Australia
Phone 150852 0
+61 403 704 912
Fax 150852 0
Email 150852 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.